PDSB News and Press, PDS Biotechnology Corporation From 06/03/21

FLORHAM PARK, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating techn...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Gainers: Washington Prime (WPG) +99%.Orbital Energy (OEG) +67%.Vertex Energy (VTNR) +28%.LexinFintech (LX) +28%.ENGlobal (ENG) +28%.New Concept Energy (GBR) +26%.Cloudera (CLDR) +24%.Aethlon Medical (AEMD) +24%.Aesthetic Medical International (AIH) +22%.Lineage Cell Therapeutics (LCTX) +...

FLORHAM PARK, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced it will h...

PDS Biotechnology Corporation (NASDAQ:PDSB) traded at a new 52-week high today of $12.46. So far today approximately 4 million shares have been exchanged, as compared to an average 30-day volume of 2 million shares. In the past 52 weeks, PDS Biotechnology Corporation share prices are bra...

Shares of PDS Biotechnology Corporation (NASDAQ:PDSB) traded at a new 52-week high today of $10.85. This new high was reached on above average trading volume as 4 million shares traded hands, while the average 30-day volume is approximately 2 million shares. PDS Biotechnology Corporation...

PDS Biotechnology (PDSB) and the Head and Neck Cancer Alliance announce a new partnership to raise awareness of new and developing treatment options for patients with HPV-attributed head and neck cancer diagnoses.PDS's lead candidate, PDS0101, uses versamune to activate the immune system...

FLORHAM PARK, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a novel therapy for HPV-associated cancer based on the Company’s proprietary Versamune® T-cell activating technology, and the Head...

PDS Biotechnology Corporation (NASDAQ:PDSB) traded today at a new 52-week high of $9.56. So far today approximately 4 million shares have been exchanged, as compared to an average 30-day volume of 2 million shares. Over the past year, PDS Biotechnology Corporation has traded in a range o...

Shares of PDS Biotechnology Corporation (NASDAQ:PDSB) traded today at $8.82, eclipsing its 52-week high. So far today approximately 4 million shares have been exchanged, as compared to an average 30-day volume of 562,000 shares. In the past 52 weeks, shares of PDS Biotechnology Corporati...